127,900 Shares in Organon & Co. (NYSE:OGN) Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new position in Organon & Co. (NYSE:OGN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 127,900 shares of the company’s stock, valued at approximately $1,844,000.

Other institutional investors have also recently bought and sold shares of the company. Quilter Plc bought a new stake in shares of Organon & Co. during the 1st quarter valued at $854,973,000. Wellington Shields Capital Management LLC bought a new stake in shares of Organon & Co. during the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd raised its position in shares of Organon & Co. by 495.5% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the last quarter. Harbour Investments Inc. raised its position in shares of Organon & Co. by 93.3% during the 2nd quarter. Harbour Investments Inc. now owns 1,976 shares of the company’s stock valued at $41,000 after acquiring an additional 954 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Organon & Co. during the 3rd quarter valued at $35,000. Institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upped their target price on shares of Organon & Co. from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, February 20th.

Organon & Co. Stock Down 0.1 %

OGN opened at $17.86 on Friday. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $24.79. The company has a fifty day simple moving average of $18.00 and a 200 day simple moving average of $15.62. The stock has a market cap of $4.57 billion, a P/E ratio of 4.47, a P/E/G ratio of 0.85 and a beta of 0.83.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. On average, equities research analysts expect that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.27%. The ex-dividend date of this dividend was Friday, February 23rd. Organon & Co.’s dividend payout ratio is currently 28.00%.

Insider Activity at Organon & Co.

In other news, insider Kirke Weaver bought 2,720 shares of the stock in a transaction on Thursday, February 22nd. The stock was purchased at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the acquisition, the insider now owns 15,181 shares in the company, valued at $278,723.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.17% of the stock is owned by corporate insiders.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.